Testing IBI3033 for Moderate-to-Severe Atopic Dermatitis
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new medication called IBI3033 for people with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with skin creams alone. The goal is to see if this drug can safely reduce itching, inflammation, and affected skin area.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate-to-severe atopic dermatitis diagnosed at least 12 months ago
- Your eczema hasn't improved enough with topical creams/ointments in the past year, or topical treatments aren't safe for you
- You are between 18 and 75 years old and weigh at least 40 kg
- Your Body Mass Index (BMI) is between 18 and 35
- If you can have children, you agree to use birth control during the study and for 6 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
This study tests a new ointment (HL-300) designed to treat mild-to-moderate atopic dermatitis (a chronic skin condition causing itching and inflammation). You would apply it to affected skin areas to see if it safely reduces symptoms.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This study tests a new medication called IBI356 for people with moderate to severe eczema that hasn't improved with standard creams. The goal is to see if this medicine can safely reduce the redness, itching, and rash.
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
This study tests a new medicine called IMG-007 for adults with moderate-to-severe eczema (atopic dermatitis) that hasn't gotten better with standard creams. The goal is to see if it safely reduces itching and skin symptoms.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.